Table 2

Distribution of antihypertensive substances in hypertension patients in the SHIP-0 cohort1to SHIP-1
Females (N = 509) Males (N = 565) Total (N = 1074)
Active agents N % (95% CI2) N % (95% CI2) N % (95% CI2)
Beta blockers 335 66.2 336 61.2 671 63.7
(61.8 – 70.5) (56.8 – 65.5) (60.6 – 66.8)
ACE-inhibitors 252 49.6 334 55.3 586 52.4
(45.0 – 54.2) (50.9 – 59.7) (49.2 – 55.6)
Diuretics 242 45.0 233 37.2 475 41.1
(40.7 – 49.4) (32.7 – 41.7) (38.0 – 44.3)
Calcium channel blocker 160 28.9 187 32.3 347 30.6
(24.9 – 32.9) (28.0 – 36.7) (27.6 – 33.6)
Angiotensin II receptor antagonists 108 20.1 98 17.3 206 18.7
(16.4 – 23.8) (13.9 – 20.6) (16.2 – 21.2)
Antiadrenergic substances3 22 4.4 34 5.4 56 4.9
(2.5 – 6.3) (3.2 – 7.7) (3.4 – 6.4)
Vasodilators4 2 0.3 1 0.2 3 0.2
(0.0 – 0.8) (0.0 – 0.5) (0.0 – 0.5)
Other types - - 1 0.2 1 0.1
(0.0 – 0.6) (0.0 – 0.3)

1Study participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and/or study participants with risk-comorbidity (diabetes, stroke, angina pectoris, and/or myocardial infarction) and blood pressure values ≥130/80 mmHg.

2CI confidence interval.

3Both peripheral and central active antiadrenergic substances.

4Only with indication hypertension.

van den Berg et al.

van den Berg et al. BMC Public Health 2013 13:594   doi:10.1186/1471-2458-13-594

Open Data